ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting
5 affiliations
- 1Department of General Surgery, Lanzhou University Second Hospital
- 2The Second Clinical Medical School, Lanzhou University
- 3Gansu Provincial Industrial Technology Center for Cancer Immunotherapy, Lanzhou University Second Hospital
- 4Gansu Tumor Immunology Basic Disciplines Research Center, The Second Hospital & Clinical Medical School, Lanzhou University
- 5Gansu Province High-Altitude High-Incidence Cancer Biobank, Lanzhou University Second Hospital
Abstract
UL16-binding protein 2 (ULBP2) is a stress-inducible ligand of natural killer group 2 member D (NKG2D) that connects cellular stress to immune surveillance. Its consequences in cancer depend on membrane accessibility, ligand density, proteolytic shedding, soluble-ligand exposure, duration of stimulation, and effector-cell fitness rather than bulk expression alone. Accessible membrane ULBP2 can support NKG2D–DAP10-dependent natural killer (NK) cell cytotoxicity and CD8 ⁺ T-cell costimulation, whereas shedding reduces cell-surface ligand and can generate soluble ULBP2 (sULBP2). Chronic surface-ligand exposure has been associated with NKG2D adaptation in heterologous mouse models; direct human in-vivo validation and quantitative exposure thresholds remain unavailable. In clinical cohorts, associations between circulating sULBP2 and prognosis do not establish that sULBP2 itself mediates immunosuppression. This review distinguishes ULBP2-specific observations from pan-NKG2D-ligand findings and platform-based extrapolations. It critically evaluates molecular regulation, immune activation and escape, biomarker assays, and CAR-based therapies, multispecific engagers, antibodies, and antibody–drug conjugates (ADCs). EVOLVE104 recognizes ULBP2/5/6 and is under phase I investigation, but the available public sources contain no mature clinical efficacy or safety outcomes; ULBP2-specific CAR-T approaches remain preclinical and ULBP2-directed ADCs lack target-developability validation. Translation will require matched measurements of surface ULBP2 and sULBP2, human-relevant normal-tissue testing, functional immune readouts, and construct-specific assessment of target selectivity, internalization, and exposure.
Related
- The SCF/KIT signaling pathway in multisystem diseases: Mechanisms and therapeutic targeting
- TREX1 in cancer immunity: from molecular mechanism to pharmacological targeting
- Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity.
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
- Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung Cancer
BibTeX
@article{han2026ulbp2nkg2d,
title = {{ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting}},
author = {Haobo Han and Weiwen Cai and Ruohan Ma and Biao Ding and Long Qin and Zuoyi Jiao},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2012358},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2012358/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting
AU - Haobo Han
AU - Weiwen Cai
AU - Ruohan Ma
AU - Biao Ding
AU - Long Qin
AU - Zuoyi Jiao
PY - 2026
DA - 2026/11/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2012358
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2012358/full
AB - UL16-binding protein 2 (ULBP2) is a stress-inducible ligand of natural killer group 2 member D (NKG2D) that connects cellular stress to immune surveillance. Its consequences in cancer depend on membrane accessibility, ligand density, proteolytic shedding, soluble-ligand exposure, duration of stimulation, and effector-cell fitness rather than bulk expression alone. Accessible membrane ULBP2 can support NKG2D–DAP10-dependent natural killer (NK) cell cytotoxicity and CD8 ⁺ T-cell costimulation, whereas shedding reduces cell-surface ligand and can generate soluble ULBP2 (sULBP2). Chronic surface-ligand exposure has been associated with NKG2D adaptation in heterologous mouse models; direct human in-vivo validation and quantitative exposure thresholds remain unavailable. In clinical cohorts, associations between circulating sULBP2 and prognosis do not establish that sULBP2 itself mediates immunosuppression. This review distinguishes ULBP2-specific observations from pan-NKG2D-ligand findings and platform-based extrapolations. It critically evaluates molecular regulation, immune activation and escape, biomarker assays, and CAR-based therapies, multispecific engagers, antibodies, and antibody–drug conjugates (ADCs). EVOLVE104 recognizes ULBP2/5/6 and is under phase I investigation, but the available public sources contain no mature clinical efficacy or safety outcomes; ULBP2-specific CAR-T approaches remain preclinical and ULBP2-directed ADCs lack target-developability validation. Translation will require matched measurements of surface ULBP2 and sULBP2, human-relevant normal-tissue testing, functional immune readouts, and construct-specific assessment of target selectivity, internalization, and exposure.
SN - 1664-3224
ER -